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ABSTRACT 45 
Objective 46 
We aimed to compare the association of hypertriglyceridemic-waist (HTGW), with 47 
glycaemia, liver and renal function between a Chinese and an Australian 48 
population using 3 HTGW definitions. 49 
Methods 50 
1,454 Australian and 5,824 Chinese adults, from randomly selected households 51 
provided clinical history, glucose, lipids, anthropometric, and blood pressure 52 
measurements. Liver and renal functions were assessed using Alanine 53 
Aminotransferase and estimated Glomerular Filtration Rate respectively. The 54 
impact of interaction between HTGW and glucose on the liver and renal functions 55 
were measured by General Linear Model. Logistic regression was used to estimate 56 
the association between this interaction and abnormal liver and renal function. 57 
Results 58 
HTGW was associated with abnormal liver and renal function in both Chinese and 59 
Australian populations using all 3 HTGW definitions.  The highest sensitivity (93 60 
(95% confidence interval: 87, 97) %) and specificity (81 (80, 84) %) were observed 61 
for abnormal renal function in the Australian population. The probability of having 62 
abnormal liver or renal function increased with glucose in the presence of HTGW 63 
phenotype only in the Australian population. Similar findings were revealed in 64 
people without type 2 diabetes. 65 
Conclusions 66 
In both Chinese and Australian populations, HTGW is associated with abnormal 67 
liver and renal function using any of the 3 definitions. HTGW is a potential tool to 68 
identify high-risk individuals with impaired renal function especially in the 69 
Australian population. HTGW interacted with the fasting glucose in its association 70 
with impaired liver and renal function only in the Australian population, 71 
suggesting different underlying interactions between environmental and genetic 72 
backgrounds. 73 
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INTRODUCTION 81 
It has been estimated that 3.4 million deaths, 3.9% of years of life lost and 3.8% of 82 
disability-adjusted life-years were caused by overweight and obesity globally in 2010 1. In 83 
spite of the well-recognized increased morbidity and mortality associated with an 84 
elevated body weight, there is clear evidence that visceral adiposity conveys the highest 85 
risk of metabolic complications, especially type 2 diabetes. Visceral adiposity 86 
accumulation (visceral obesity) rather than subcutaneous (non-visceral) obesity is 87 
associated with increased risk of chronic kidney disease 2, 3 and metabolic liver disease 4.  88 
Although BMI is easy to calculate, it is a poor estimate of fat mass and its distribution, as 89 
muscular individuals or those with more subcutaneous fat may have a BMI as high as 90 
individuals with larger visceral adiposity. From a risk standpoint, there is now evidence 91 
that the simultaneous presence of an elevated waist circumference and fasting 92 
triglyceride (known as the hypertriglyceridemic waist, HTGW) may represent a phenotype 93 
for visceral obesity. So far, there are three definitions developed in diverse populations 94 
and utilised to identify individuals at higher risk of metabolic disorders 5, 6, 7. Although the 95 
concept of the HTGW was proposed in 2000 8, its association with other features of 96 
visceral obesity including abnormal liver and renal function, and the extent of any 97 
interaction with fasting hyperglycaemia remain undefined. Moreover, since different 98 
definitions of HTGW were derived from different ethnic groups, it is unclear whether 99 
these different definitions were due to the study specific analyses or genuine ethnic 100 
variations.  Our study now aims to address these uncertainties by comparing the 101 
relationships between HTGW phenotypes and abnormal liver and renal function, and any 102 
associated interactions with fasting glucose between two populations: one Chinese  and 103 
one predominantly  Australian of European descent. 104 
MATERIALS AND METHODS 105 
 106 
 4 
Data setting 107 
 108 
The Australian population data were derived from the Crossroads study (>98% European 109 
descent) 9 carried out between June 2001 and March 2003 among residents of the seven 110 
main towns in the Goulburn Valley, Victoria, Australia (populations 2094–35,828), as 111 
previously described 8,9,10. A two-step approach was used: interviews were conducted 112 
with all residents in randomly selected households (a ‘census’) and then invitations were 113 
given for all usual residents (resident in the area for at least 6 months) aged ≥ 25 years to 114 
attend for a ‘clinic’. An initial census of 2376 randomly selected households (half in the 115 
regional centre, a twelfth in each of the six smaller towns) was undertaken (response 116 
rate 70%). Houses were revisited until a response was received. 117 
 118 
The Chinese population data were derived from the Nanjing Community Cardiovascular 119 
Risk Survey, using random cluster sampling11, between July 2011 and April 2013 among the 120 
residents of 6 communities in Nanjing, Jiangsu Province, China (population 0.7 million-1.3 121 
million). In each community, one street district or township was randomly selected. All 122 
households (n=6,445) in the selected street or town were included with only one 123 
participant aged ≥ 20 years selected from each household, without replacement. Overall, 124 
5,824 residents completed the survey and examination (response rate of 90%).  125 
 126 
In both studies, questionnaires were completed, wherever possible, through face-to-face 127 
interviews by trained research staff. Questions included age, sex, ethnicity, education, 128 
and known diabetes. 129 
 130 
In both studies, blood pressure and body measurements including height, weight, and 131 
waist circumference were taken three times using a standardized methodology on the 132 
same day in the local clinical center and the mean of the two closest recordings was used. 133 
 5 
Height, weight, and waist circumference were measured by use of a metric scale and a 134 
vertical weight scale. Weight was measured in light indoor clothing without shoes to the 135 
nearest 10th of a kilogram. Height was measured without shoes to the nearest 10th of a 136 
centimetre. Waist circumference was measured at 1 cm above the navel at minimal 137 
respiration. In both studies all observers participated in a training session on the use of a 138 
standardized protocol for anthropometric measurement techniques. 139 
  140 
Fasting blood specimens were collected using a vacuum tube containing sodium fluoride. 141 
The fasting time was verified prior to collecting the blood specimen. Participants who had 142 
not fasted for at least 10 h did not have their blood drawn and processed at the 143 
examination center (Nanjing) or a centralized Laboratory (Crossroads), where the 144 
specimens were stored at −70°C until laboratory assays could be carried out. Plasma 145 
glucose, alanine aminotransferase (ALT), creatinine, and lipid levels were measured by 146 
automated analyser (Australian: Hitachi 917R autoanalyser (Hitachi, Tokyo, Japan); 147 
Nanjing: Olympus AU600 autoanalyser (Olympus Optical, Tokyo, Japan)). Type 2 diabetes 148 
was defined using WHO criteria 10 or by self-report if previously diagnosed (confirmed by 149 
doctor prescription (Nanjing) or medical records (Crossroads)), and metabolic syndrome 150 
(MS) using International Diabetes Federation (IDF) criteria 11. Hypertension was 151 
considered present if reported as having previously been diagnosed by a doctor or nurse 152 
12.  The estimated Glomerular Filtration Rate (eGFR) was calculated from serum creatinine 153 
using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation 13. Due 154 
to non-standardised creatinine measurement, (Isotope Dilution Mass Spectrometry 155 
(IDMS) standardized creatinine assay) adjusted creatinine was applied in the eGFR 156 
estimation in the Crossroads study 14. Abnormal liver function was defined as ALT ≥ 40U/L 157 
15 and abnormal renal function was defined as eGFR < 60 ml/min/1.73m2 16. 158 
 159 
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The exposure ‘HTGW’  were defined in three ways: (“Definition-1”) both men and women: 160 
WC ≥ 85 cm andtriglyceride (TG) ≥ 1.5 mmol/L (133 mg/dl) 5; (“Definition-2”) for men, WC 161 
≥90 cm and TG ≥2.0 mmol/L(177mg/dl) ; for women, WC ≥85 cm and TG≥1.5 mmol/L(133 162 
mg/dl) 6; (“Definition-3”) for men: WC ≥ 90cm and TG ≥ 2.0 mmol/L (177mg/dl); for 163 
women, WC≥85cm and TG≥ 2.0 mmol/L (177mg/dl) 7. 164 
 165 
Statistical analysis 166 
Continuous variables were characterized by their mean and standard deviation, and 167 
differences across groups were tested using Student’s t test. Binary factors were 168 
characterized by percentages, and difference across groups were tested using Fisher’s 169 
exact test. 170 
 171 
Associations between the three HTGW definitions and abnormal liver and renal function 172 
were assessed by logistic regression after adjusting for age, gender and BMI. Since the 173 
number of HTGW cases and normal samples were severely unbalanced in most cases, 174 
weighted logistic regression was performed with higher weight on samples from the 175 
smaller group to achieve similar prediction rates in both the case and normal groups. 176 
Odds ratio (OR), as the measurement between exposures (HTGW and glucose) and 177 
outcomes (abnormal liver and renal function), and the confidence interval, were 178 
calculated from the regression coefficient for HTGW and its standard deviation. 179 
Predictions from the regression model were compared with the observed values to 180 
obtain the prediction sensitivities and specificities. The estimated sensitivity/specificity 181 
and their confidence intervals were calculated. The sensitivity is defined as the proportion 182 
of patients with abnormal liver and renal function having the HTGW phenotype. The 183 
specificity is defined as the proportion of patients without abnormal liver and renal 184 
function who did not have the HTGW phenotype. 185 
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 186 
The relationships between fasting glucose and the outcomes (continuous outcomes: ALT 187 
and eGFR; binary outcomes: abnormal liver function and abnormal renal function) were 188 
modelled for the dose-response effect using fractional polynomials. Sensitivity analyses 189 
were performed to refit the models within the data rich range (5th percentile to 95th 190 
percentile). In another sensitivity analysis, all analyses were performed among 191 
participants without diabetes. We have a 95% chance of detecting 10% increased risk of 192 
abnormal renal/liver function in HTGW subjects at an alpha level of 0.05. All analyses were 193 
conducted using R, CRAN version 3.2.2 with P < 0.05 considered statistically significant. 194 
 195 
The Goulburn Valley Health Ethics Committee approved the Crossroads study (approval 196 
number GVH – 3/99). The Institutional Review Board of Jiangsu Province Hospital on 197 
Integration of Chinese and Western Medicine approved the Nanjing study (approval 198 
number 11-006).  Signed, informed consent was obtained from all participants.   199 
 200 
RESULTS 201 
 202 
The characteristics of the study participants by the three HTGW phenotype definitions in 203 
both the Chinese and Australian populations are presented in Table-1. Irrespective of 204 
definitions of HTGW phenotypes, participants with HTGW were more likely to have higher 205 
age, WC, body mass index, fasting glucose, triglycerides, and low-density lipoprotein, and 206 
lower levels of high-density lipoprotein both in the Chinese and Australian populations. 207 
The prevalence of metabolic disorders (metabolic syndrome or type 2 diabetes) was 208 
higher among participants with the HTGW phenotype both in the Chinese and Australian 209 
populations. Chinese participants with HTGW defined by Definition-1, and Australian 210 
participants with HTGW defined by Definition-1 and Definition-3, respectively were more 211 
likely to be men. 212 
 8 
 213 
Higher concentrations of ALT and a reduced eGFR were more common among 214 
participants with HTGW phenotypes irrespective of definitions of HTGW in both Chinese 215 
and Australian populations (Figure S1). 216 
 217 
The associations between presence of HTGW phenotypes and abnormal liver and renal 218 
function are presented in Table-2. Having HTGW phenotype was significantly associated 219 
with a higher odds ratio of abnormal liver function by each definition of HTGW in the 220 
Chinese population, and by Definition-1 and Defition-3 in the Australian population. 221 
Having HTGW phenotype was only significantly associated with a higher odds ratio of 222 
abnormal renal function by Definition-2 and only in the Chinese population (Table-2). In 223 
the stratified analysis, having HTGW phenotype was more likely to be significantly 224 
associated with a higher odds ratio of abnormal renal function and liver function among 225 
those with high fasting plasma glucose (FPG≥5.6 mmol/L) (Figure-1). 226 
 227 
Utilization of the HTGW phenotype to screen for abnormal liver function was tested by 228 
the three definitions.   The highest sensitivity was found using Definition-2 both in Chinese 229 
and Australian populations, and the highest specificity using Definition-1 in the Chinese 230 
population and using Definition-3 in the Australian population. Screening for abnormal 231 
renal function using HTGW phenotypes was also tested using the three definitions, with 232 
similar sensitivity and specificity in both the Chinese and Australian populations (Table-2).  233 
 234 
The dose-response relationships between ALT and fasting glucose were observed among 235 
participants with and without the HTGW phenotype by the three definitions both in the 236 
Chinese and Australian populations (Figure-S2). Among Australian participants with the 237 
HTGW phenotype, ALT tended to be stable using the fasting glucose with glucose 238 
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concentrations below 5.5 mmol/L, and increased with glucose concentrations above 5.5 239 
mmol/L. Among Australian participants without phenotype, ALT increased with the 240 
glucose at glucose concentrations below 5.5 mmol/L and tended to be stable with 241 
glucose concentrations above 5.5 mmol/L. Among Chinese participants with or without 242 
HTGW phenotype, ALT tended to be stable at glucose concentrations below 6.0 mmol/L 243 
and increased as glucose increasedat concentrations above 6.0 mmol/L (Figure S3). 244 
 245 
The dose-response relationships between eGFR and glucose were observed among 246 
participants with and without HTGW phenotype using the three definitions in both the 247 
Chinese and Australian populations (Figure-S4).  Among Australian participants with the 248 
HTGW phenotype, eGFR decreased as glucose increased at glucose concentrations below 249 
6.7 mmol/L and tended to be stable at glucose concentrations above 6.7 mmol/L. Among 250 
Australian participants without the HTGW phenotype, eGFR decreased asglucose 251 
increased below 5.5 mmol/L and then tended to be stable at glucose concentrations 252 
above 5.5 mmol/L. Among Chinese participants with or without HTGW phenotype, the 253 
eGFR decreased as glucose increased below 5.5 mmol/L and tended to be stable at 254 
glucose concentrations above 5.5 mmol/L.  255 
 256 
The dose-response relationship between the glucose level and log odds ratio of having 257 
abnormal liver function is presented in Figure-2. Among Australian participants with the 258 
HTGW phenotype, the log odds ratio of having abnormal liver function decreased as 259 
glucose increased up to 5.5 mmol/L and then increased as glucose increased. Among 260 
Australian participants without the HTGW phenotype, the log odds ratio of having 261 
abnormal liver function decreased as glucose increased up to 5.5 mmol/L and then tended 262 
to be stable. Among Chinese participants with or without the HTGW phenotype, the log 263 
odds ratio decreased as the glucose increased up to 5.5 mmol/L and then increased 264 
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 265 
The dose-response relationships between the log odds ratio of abnormal renal function 266 
and fasting glucose were observed among participants with and without the HTGW 267 
phenotype by the three definitions in both the Chinese and Australian populations 268 
(Figure-3). Among Australian participants with the HTGW phenotype, the log odds ratio 269 
of abnormal renal function decreased with increasing fasting glucose up to 6.0 mmol/L 270 
and increased thereafter. Among Australian participants without the HTGW phenotype, 271 
the log odds ratio of abnormal renal function increased as the fasting glucose increased 272 
up to 5.0 mmol/L and then tended to be stable. Among Chinese participants with and 273 
without the HTGW phenotype, the log odds ratio of abnormal renal function decreased 274 
asthe fasting glucose increased up to 5.0 mmol/L and then increased.  275 
 276 
All dose-response relationships were analysed in the data rich range with similar findings 277 
as shown as Figures S5-S7. 278 
 279 
All dose-response relationships were analysed among participants without diabetes, and 280 
the same shapes of dose-response curves and thresholds were identified Figure S8-S11. 281 
 282 
DISCUSSION 283 
 284 
Using two independent populations, we found that the HTGW phenotype, 285 
defined by each of three definitions, was associated with abnormal liver and renal 286 
function in both the Chinese and the Australian populations.   However, the 287 
patterns of these relationships differed.   Among the Australians, but not the 288 
Chinese, the HTGW phenotype could be used to screen for abnormal renal 289 
function with high sensitivity and specificity.  Among Australians, the ALT 290 
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increased and eGFR decreased (ie the probability of having abnormal liver or renal 291 
function increased) with increasing fasting glucose, especially in the presence of 292 
the HTGW defined by each definition.   No such relationships were found in the 293 
Chinese cohort with or without HTGW and using any HTGW definition.   294 
 295 
Visceral obesity is thought to play a key role in the pathway to developing 296 
metabolic disorders (metabolic syndrome or type 2 diabetes) 17. The HTGW 297 
concept was developed as a proxy for visceral obesity, and has previously been 298 
shown to be associated with hypertension, metabolic syndrome, type 2 diabetes, 299 
atherosclerosis and several other disorders 18. In an Iranian cross-sectional study, 300 
the HTGW, defined by Definition-3, was found to be associated with chronic 301 
kidney disease 19. In the Insulin Resistance Atherosclerosis Study, the HTGW was 302 
associated with an elevated ALT 20. However, it has been unclear whether these 303 
associations were independent of fasting glycaemia, another correlate of 304 
abnormal liver and renal function. In our study, the HTGW phenotype was 305 
associated with abnormal liver and renal function both in the Chinese and 306 
Australian populations.   We have now shown heterogeneity in in the interaction 307 
between the HTGW phenotype and the fasting glucose, as it was only present in 308 
the Australian, not the Chinese population.  This suggests that HTGW and fasting 309 
glucose have independent impacts on the development of abnormal liver and 310 
renal function.    311 
 312 
Definition-2 (for men, WC ≥90 cm and TG ≥2.0 mmol/L(177mg/dl) ; for women, WC 313 
≥85 cm and TG≥1.5 mmol/L(133 mg/dl)) appeared to be the optimal definition and 314 
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therefore could be an effective screening tool to identify individuals who are 315 
potentially at high risk of developing abnormal liver and/or renal function.   316 
Definition 2 had both high sensitivity and specificity, particularly for abnormal 317 
renal function, in the Australian population. The relatively low sensitivity and 318 
specificity of HTGW in the Chinese population might be due to the relatively low 319 
waist circumference and triglyceride concentrations, which also hints at the 320 
potential for future exploration for appropriate definitions of HTGW in Chinese 321 
population 21. 322 
  323 
Several mechanisms may contribute to the findings of this study. Impaired liver 324 
and renal function might result from an altered systemic balance between 325 
inflammatory factors and adipokines, as both the acute-phase inflammatory 326 
reactant, C-reaction protein, and the proinflammatory cytokines, such as TNF-α 327 
and IL-6 were previously found to be associated with HTGW phenotype 22. On the 328 
other hand, a decreased adiponectin level was found to be associated with HTGW 329 
phenotype 22.  Adiponectin, the only adipokine inversely associated with 330 
metabolic disorders including insulin resistance, is a signalling protein that is 331 
predominantly synthesized and secreted by adipose tissue and is one of the most 332 
abundant plasma proteins in humans 23. 333 
 334 
The principal limitation of the present study is the use of cross-sectional data in 335 
both China and Australia, whereby HTGW phenotypes and abnormal liver and 336 
renal function were assessed at the same time. It is difficult to make causal 337 
inference between HTGW and impaired liver and renal function.  The role of 338 
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HTGW in screening for abnormalities were emphasized in the current analysis 339 
particularly among Australians. Analysis of longitudinal data would be the next 340 
step in examining these relationships further. Another limitation of this joint study 341 
is that the data were not collected within the same survey, although the data do 342 
appear to be comparable. Although the clinical measurements were managed 343 
using a standard approach in both China and Australia, the two research teams 344 
worked independently, processing the measurements and blood samples using 345 
different equipment including automated analysers.  The laboratories were both 346 
involved in their respective national laboratory quality assurance programmes and 347 
would have therefore had external quality controls on the precision and accuracy 348 
of their analyses. The temporal difference in data collection from the two 349 
countries might also have some impact on the research population.  350 
Finally, the conventional methods (stratification analyses and multivariable 351 
modelling strategy) to adjust more confounders were restricted by the current 352 
sample size (especially low outcome counts per variable). Therefore, the 353 
adjustment of more covariables or potential confounders in the current models 354 
was not optional and future external validation studies with further adjustment of 355 
more confounders, alongside a meta-analysis are needed to better determine 356 
whether HTGW does have the potential to be used as a simple screening tool in 357 
clinical practice. 358 
 359 
In conclusion, both in the Chinese and Australian population, HTGW was found to 360 
be associated with abnormal liver and renal functions using three previously 361 
developed definitions. HTGW has the potential as a screening tool to identify 362 
 14 
individuals at high risk of impaired renal function particularly in the Australian 363 
population. Only in the Australian population, did the HTGW interact with fasting 364 
glucose in its associations with impaired liver and renal function.  365 
 366 
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FIGURE LEGENDS 
Figure-1. Adjusted associations between hyperglyceridaemic waist phenotype definitions and abnormal liver and renal function by fasting 
plasma glucose level 
 Age and body mass index were adjusted. Point estimation (95% confidence interval) was presented for each measurement. 
HTGW definition 1 :both men and women: WC ≥ 85 cM & a triglyceride (TG) ≥ 1.5 mmol/L (133 mg/dl)); HTGW definition 2: for men, WC ≥90 cM and TG ≥2.0 mmol/L(177mg/dl) ; for women, WC 
≥85 cM and TG≥1.5 mmol/L(133 mg/dl); and HTGW definition 3: for men: WC ≥ 90cM and TG ≥ 2.0 mmol/L (177mg/dl); for women, WC>=85cM and TG≥ 2.0 mmol/L (177mg/dl). 
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Figure-2. Dose-response curves between abnormal liver function and glucose by hypertriglyceridaemic waist phenotype definitions   
The area indicates the distribution of fasting glucose (cyan area for Australian population; red area for Chinese population). The adjusted log odds ratio of having abnormal liver function 
(solid line) and the 95% confidence interval (dot line) from Logistic Regression Model with adjustment of age and body mass index (cyan line for Australian population and red line for Chinese 
population). The upper panel indicates association between glucose and abnormal liver function among those with HTGW phenotypes; the below panel indicates association between glucose 
and abnormal liver function among those without HTGW phenotypes. The three columns represent three definitions: left column indicates the HTGW definition 1 (both men and women: WC ≥ 
85 cM & a triglyceride (TG) ≥ 1.5 mmol/L (133 mg/dl)); middle column indicates the HTGW definition 2 (for men, WC ≥90 cM and TG ≥2.0 mmol/L(177mg/dl) ; for women, WC ≥85 cM and TG≥1.5 
mmol/L(133 mg/dl)); and the right column indicates the HTGW definition 3 (for men: WC ≥ 90cM and TG ≥ 2.0 mmol/L (177mg/dl); for women, WC>=85cM and TG≥ 2.0 mmol/L (177mg/dl)). 
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Figure-3. Dose-response curves between abnormal renal function and glucose by hypertriglyceridaemic waist phenotype definitions  
The area indicates the distribution of fasting glucose (cyan area for Australian population; red area for Chinese population). The adjusted log odds ratio of having abnormal renal function 
(solid line) and the 95% confidence interval (dot line) from Logistic Regression Model with adjustment of age and body mass index (cyan line for Australian population and red line for Chinese 
population). The upper panel indicates association between glucose and abnormal renal function among those with HTGW phenotypes; the below panel indicates association between 
glucose and abnormal renal function among those without HTGW phenotypes. The three columns represent three definitions: left column indicates the HTGW definition 1 (both men and 
women: WC ≥ 85 cM & a triglyceride (TG) ≥ 1.5 mmol/L (133 mg/dl)); middle column indicates the HTGW definition 2 (for men, WC ≥90 cM and TG ≥2.0 mmol/L(177mg/dl) ; for women, WC ≥85 
cM and TG≥1.5 mmol/L(133 mg/dl)); and the right column indicates the HTGW definition 3 (for men: WC ≥ 90cM and TG ≥ 2.0 mmol/L (177mg/dl); for women, WC>=85cM and TG≥ 2.0 mmol/L 
(177mg/dl)). 
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TABLES 
Table-1. Characteristics of study participants by hyperglyceridaemic waist phenotype definitions  
 Country Characteristics* 
Definition-1 Definition-2 Definition-3 
No Yes P-values No Yes P-values No Yes P-values 
 N 4773 983 --- 5074 682 ---- 5267 489 ---- 
China 
Gender, Female % 2759 (57.8)  481 (48.9) <0.001 2760 (54.4)  481 (70.5) P<0.001 2955 (56.1)  288 (58.9) 0.230 
Age, years 51.37(9.89)   53.71(9.55) <0.001 51.47(9.92)   54.02(9.22) P<0.001 51.6(9.91)   53.61(9.25) <0.001 
Waist circumference, cm 78.25(8.59)   91.95(5.91) <0.001 78.97(8.89)   92.65(6.14) P<0.001 79.44(9.17)   92.96(5.55) <0.001 
Body mass index, kgm2 23.3(3.83)   27.37(3.37) <0.001 23.47(3.83)   27.88(3.57) P<0.001 23.63(3.88)   27.92(3.79) <0.001 
Fasting Glucose, mmol/L 5.53(1.26)   6.04(1.68) <0.001 5.55(1.29)   6.08(1.67) P<0.001 5.56(1.29)   6.21(1.81) <0.001 
Systolic blood pressure, mmHg 129.04(20.24)   139.47(20.75) <0.001 129.53(20.31)   140.39(21.08) P<0.001 129.89(20.47)   140.81(20.57) <0.001 
Diastolic blood pressure, mmHg 80.36(11.36)   87.34(11.99) <0.001 80.71(11.46)   87.82(12.07) P<0.001 80.88(11.52)   88.75(11.92) <0.001 
Total cholesterol, mmol/L 4.38(0.84)   4.84(0.98) <0.001 4.4(0.84)   4.9(1.01) <0.001 4.41(0.85)   4.94(1.05) <0.001 
High density lipoprotein, mmol/L 1.33(0.31)   1.23(0.3) <0.001 1.33(0.31)   1.22(0.3) <0.001 1.32(0.31)   1.19(0.3) <0.001 
Low density lipoprotein, mmol/L 2.46(0.68)   2.35(0.85) <0.001 2.45(0.69)   2.33(0.85) <0.001 2.46(0.7)   2.18(0.86) <0.001 
Triglyceride, mmol/L 1.25(1.04)   2.82(1.77) <0.001 1.32(1.11)   2.99(1.85) <0.001 1.33(1.09)   3.5(1.96) <0.001 
Metabolic disorders, n (%) 1136 (23.8) 675 (68.7) <0.001 1223 (24.1) 590 (86.5) <0.001 1401 (26.6) 413 (84.5) <0.001 
Abnormal liver function, n (%) 200 (4.2) 115 (11.7) <0.001 235 (4.6) 80 (11.7) <0.001 244 (4.6) 71 (14.5) <0.001 
Abnormal renal function, n (%) 619 (13.0) 201 (20.4) <0.001 662 (13.0) 158 (23.2) <0.001 717 (13.6) 103 (21.1) <0.001 
Australia 
N 902 552 --- 1021 433 --- 1158 296 --- 
Gender, female% 550 (61.0) 269 (48.7) <0.001 550 (53.9) 629 (62.1) 0.0038 687 (59.3) 132 (44.6) <0.001 
Age, years 51.49(16.22)   55.21(14.38) <0.001 51.9(16.13)   55.27(14.18) <0.001 52.6(16.08)   54.1(13.78) 0.110 
Waist circumference, cm 
89.93(16.19)  
 
100.86(13.08) 
<0.001 91.58(16.24)   99.98(13.68) <0.001 91.73(15.94)   103.27(12.48) <0.001 
Body mass index, kgm2 26.75(5.06)   29.74(5) <0.001 27.01(4.97)   29.96(5.28) <0.001 27.23(5.09)   30.45(5.04) <0.001 
Fasting Glucose, mmol/L 5.16(0.91)   5.72(1.61) <0.001 5.18(0.91)   5.82(1.75) <0.001 5.2(0.93)   6.03(1.94) <0.001 
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Systolic blood pressure, mmHg 128.69(21.8)   136.8(22.6) <0.001 129.84(21.78)   136.32(23.36) <0.001 130.42(22.18)   137.03(22.75) <0.001 
Diastolic blood pressure, mmHg 70.75(9.74)   74.53(10.35) <0.001 71.38(9.87)   74.08(10.51) <0.001 71.34(9.91)   75.47(10.35) <0.001 
Total cholesterol, mmol/L 5.08(0.89)   5.63(1.08) <0.001 5.11(0.91)   5.71(1.1) <0.001 5.17(0.93)   5.76(1.16) <0.001 
High density lipoprotein, mmol/L 1.54(0.38)   1.25(0.3) <0.001 1.5(0.38)   1.26(0.32) <0.001 1.5(0.37)   1.16(0.27) <0.001 
Low density lipoprotein, mmol/L 3.1(0.79)   3.35(0.95) <0.001 3.13(0.8)   3.35(0.97) <0.001 3.16(0.82)   3.34(1.01) 0.0069 
Triglyceride, mmol/L 0.96(0.29)   2.35(1.34) <0.001 1.04(0.36)   2.53(1.46) <0.001 1.11(0.39)   2.95(1.61) <0.001 
Metabolic disorders, n (%) 171 (19.0) 393 (71.2) <0.001 234 (22.9)  330 (76.2) <0.001 309 (26.7) 255 (86.1) <0.001 
Abnormal liver function, n (%) 80 (8.9) 100 (18.1) <0.001 107 (10.5) 73 (16.9) <0.001 116 (10.0) 64 (21.6) <0.001 
Abnormal renal function, n (%) 74 (8.2) 65 (11.8) <0.001 87 (8.5) 52 (12.0) <0.001 106 (9.2) 33 (11.1) <0.001 
 
 
* Continuous variables were presented as means (standard deviation). Categorical variables were presented as percentage. Metabolic disorder indicates metabolic syndrome or type 2 
diabetes. 
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Table-2. Adjusted associations between hyperglyceridaemic waist phenotype definitions and abnormal liver and renal function 
Age and body mass index were adjusted. Point estimation (95% confidence interval) was presented for each measurement. 
 
  
  
  
Definition-1 Definition-2 Definition-3 
A
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r 
fu
n
ct
io
n
 
China 
Odds ratio 2.07 (1.34 to 3.21) 1.72 (1.05 to 2.82) 2.24 (1.30 to 3.86) 
Sensitivity 0.57 (0.52 to 0.63) 0.58 (0.52 to 0.63) 0.56 (0.51 to 0.62) 
1 - specificity 0.28 (0.27 to 0.30) 0.32 (0.31 to 0.33) 0.30 (0.28 to 0.31) 
Australia 
Odds ratio 2.00 (1.24 to 3.23) 1.51 (0.92 to 2.47) 2.09 (1.22 to 3.59) 
Sensitivity 0.59 (0.52 to 0.67) 0.63 (0.56 to 0.70) 0.62 (0.54 to 0.69) 
1 - specificity 0.35 (0.32 to 0.37) 0.34 (0.32 to 0.37) 0.32 (0.30 to 0.35) 
A
b
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China 
Odds ratio 1.20 (0.86 to 1.66) 1.46 (1.01 to 2.09) 1.23 (0.81 to 1.87) 
Sensitivity 0.73 (0.70 to 0.764) 0.74 (0.71 to 0.77) 0.74 (0.71 to 0.77) 
1 - specificity 0.32 (0.31 to 0.33) 0.31 (0.30 to 0.33) 0.32 (0.31 to 0.33) 
Australia 
Odds ratio 1.41 (0.64 to 3.1) 1.60 (0.71 to 3.64) 1.60 (0.61 to 4.18) 
Sensitivity 0.92 (0.86 to 0.96) 0.93 (0.87 to 0.97) 0.93 (0.87 to 0.97) 
1 - specificity 0.18 (0.16 to 0.20) 0.18 (0.16 to 0.20) 0.18 (0.16 to 0.20) 
 
